Longevity Health Holdings, Inc. (XAGEW) — SEC Filings
Longevity Health Holdings, Inc. (XAGEW) — 50 SEC filings. Latest: 8-K (Dec 12, 2025). Includes 25 8-K, 9 SC 13G/A, 6 10-Q.
View Longevity Health Holdings, Inc. on SEC EDGAR
Overview
Longevity Health Holdings, Inc. (XAGEW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: Longevity Health Holdings, Inc. filed an 8-K on December 12, 2025, reporting the termination of a material definitive agreement as of December 8, 2025. The company, formerly known as Carmell Corp and Carmell Therapeutics Corp, is incorporated in Delaware and headquartered in Pittsburgh, PA.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Longevity Health Holdings, Inc. is neutral.
Filing Type Overview
Longevity Health Holdings, Inc. (XAGEW) has filed 25 8-K, 6 10-Q, 2 10-K/A, 2 10-K, 2 DEF 14A, 9 SC 13G/A, 1 S-1/A, 1 S-1, 2 SC 13G with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of XAGEW's 39 recent filings, 8 were flagged as high-risk, 20 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,439,829 |
| Net Income | -$4,822,060 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $1,109,228 |
| Operating Margin | N/A |
| Total Assets | $3,298,979 |
| Total Debt | $7,276,342 |
Key Executives
- Pittsburgh, Pennsylvania
Industry Context
Longevity Health Holdings operates in the health and wellness sector, which is characterized by increasing consumer demand for innovative products and services. The integration of Elevai Skincare suggests a strategic move into the beauty and skincare market, a segment known for its competitive dynamics and reliance on brand building and marketing. Companies in this space often face challenges related to product development cycles, regulatory compliance, and scaling operations to meet market demand.
Top Tags
corporate-action (8) · corporate-actions (6) · delisting (5) · SEC Filing (5) · listing-standards (4) · material-agreement (4) · financials (4) · 10-Q (4) · corporate-governance (4) · Carmell Corp (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $1,429,755 | Reduced from $2,878,481 in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $4,822,060 | Reduced from $9,453,978 in the same period of 2024 |
| Net sales for Q3 2025 | $425,864 | Increased from $20,519 in Q3 2024 |
| Net sales for nine months ended Sept 30, 2025 | $1,439,829 | Increased from $32,839 in the same period of 2024 |
| Cash as of Sept 30, 2025 | $1,109,228 | Increased from $157,139 at Dec 31, 2024 |
| Net cash provided by financing activities | $4,139,212 | For the nine months ended Sept 30, 2025 |
| Total liabilities as of Sept 30, 2025 | $7,276,342 | Exceeds total assets |
| Total stockholders' deficit as of Sept 30, 2025 | $3,977,363 | Indicates negative equity |
| Shares of common stock outstanding | 1,781,738 | As of November 12, 2025 |
| Reverse stock split ratio | 1:30 | Effected on May 12, 2025 |
| Net sales for six months ended June 30, 2025 | $1,013,965 | Increased significantly from $12,320 in the prior-year period due to Elevai Acquisition. |
| Net loss for six months ended June 30, 2025 | $3,392,305 | Widened from $6,575,497 in 2024 (which included discontinued operations). |
| Cash as of June 30, 2025 | $1,551,199 | Increased from $157,139 at December 31, 2024, primarily from stock issuance. |
| Proceeds from issuance of Common Stock, net of costs | $3,397,476 | Key driver of cash increase during the six months ended June 30, 2025. |
| Reverse Stock Split Ratio | 1:30 | Effected on May 12, 2025, to combine shares. |
Forward-Looking Statements
- {"claim":"Carmell Corp.'s stock price may experience downward pressure due to the institutional exit.","entity":"Carmell Corp.","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Longevity Health Holdings, Inc. (XAGEW)?
Longevity Health Holdings, Inc. has 50 recent SEC filings from Feb 2024 to Dec 2025, including 25 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XAGEW filings?
Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Longevity Health Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Longevity Health Holdings, Inc. (XAGEW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Longevity Health Holdings, Inc.?
Key financial highlights from Longevity Health Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XAGEW?
The investment thesis for XAGEW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Longevity Health Holdings, Inc.?
Key executives identified across Longevity Health Holdings, Inc.'s filings include Pittsburgh, Pennsylvania.
What are the main risk factors for Longevity Health Holdings, Inc. stock?
Of XAGEW's 39 assessed filings, 8 were flagged high-risk, 20 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Longevity Health Holdings, Inc.?
Recent forward-looking statements from Longevity Health Holdings, Inc. include guidance on {"claim":"Carmell Corp.'s stock price may experience downward pressure due to the institutional exit.","entity":"Carmell.